Marshall Wace

George House, 131 Sloane Street
London, SW1X 9AT

Website: mwam.com

Firm Size

• Assets Under Management (AUM):$134.5 Billion
• Number of Funds:77
• Employees:
• Firm Type:Hedge Fund

Description

Marshall Wace LLP is a hedge fund management company based in London, United Kingdom. The firm was founded in 1997 by Paul Marshall and Ian Wace and has since grown to become one of the largest and most successful hedge fund managers in Europe. The company focuses on long/short equity strategies and employs a systematic and disciplined investment approach. It combines fundamental research with proprietary trading models to make investment decisions. Marshall Wace manages a range of funds, including its flagship Marshall Wace Tops funds, which invest in large-cap European companies. With a strong emphasis on technology and data-driven decision-making, Marshall Wace has been at the forefront of using technology to enhance its investment processes. The company employs sophisticated algorithms and quantitative models to identify investment opportunities and manage risk effectively. Marshall Wace has built a reputation for its strong performance, delivering consistent returns to its investors over the years. The firm's success has attracted a diverse range of institutional and individual investors from around the globe. In addition to its investment activities, Marshall Wace is actively involved in philanthropic initiatives through its charitable arm, the Marshall Wace Charitable Foundation. The foundation focuses on addressing issues such as education, healthcare, and social welfare. Overall, Marshall Wace LLP is a renowned hedge fund management company in London, known for its systematic approach, technology-driven strategies, and successful track record in delivering returns to its investors.

Latest News

Powered by

Sep 07, 2023: BlueWhale Bio Founded with $18M Financing led by Danaher Ventures to Accelerate Cell Therapy Manufacturing
BlueWhale Bio, Inc., a new company spun out of the University of Pennsylvania to overcome key bottlenecks in cell and gene therapy manufacturing, announced today that it has raised $18 million in Seed financing. The round was led by Danaher Ventures LLC, the corporate venture subsidiary of Danaher Corporation, with a deep syndicate of leading life science investors, including Novalis LifeSciences and Marshall Wace , amongst others.